Lockheed Martin Investment Management Co. Has $6.24 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Lockheed Martin Investment Management Co. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 286.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 72,550 shares of the company’s stock after buying an additional 53,800 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Novo Nordisk A/S were worth $6,241,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter worth $48,000. Dunhill Financial LLC increased its holdings in shares of Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares in the last quarter. Finally, Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $82.60 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s 50-day simple moving average is $93.12 and its 200 day simple moving average is $112.54. The stock has a market cap of $370.65 billion, a price-to-earnings ratio of 26.73, a PEG ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on NVO shares. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.